臨床泌尿器科70巻2号

2016年02月発行

特集 ここが知りたい! 筋層非浸潤性膀胱癌─エキスパートが答える日常診療の疑問点

〈初発腫瘍に対する治療方針〉

中間リスク群

著者： 松本洋明¹ 松山豪泰¹

所属機関： ¹山口大学大学院医学系研究科泌尿器科学分野

ページ範囲：P.144 - P.149

文献概要

質問 : 初発中間リスク群NMIBCの場合，再発予防には抗がん剤膀胱内注入とBCG膀胱内注入とどちらが推奨されるのでしょうか？

▶ポイント

・中リスク筋層非浸潤性膀胱癌は，経尿道的膀胱腫瘍切除術のみでは高い再発率が問題となる．

・術直後に抗がん剤膀胱内単回投与に引き続き，維持膀注療法を行うことで再発を低減できる可能性がある．

・症例によってはBCG膀胱内注入療法も選択肢として考慮し，再発予防とともに進展抑制を図ることが患者の予後やQOL改善に重要である．

参考文献

1） 日本泌尿器科学会（編） : 膀胱癌診療ガイドライン 2015年版. 医学図書出版, 東京, 2015

2） Gudjonsson S, Adell L, Merdasa F, et al : Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study. Eur Urol 55 : 773─780, 2009

3） Hinotsu S, Akaza H, Ohashi Y, et al : Intravesical chemotherapy for maximum prophylaxis of new early phase superficial bladder carcinoma treated by transurethral resection : a combined analysis of trials by the Japanese Urological Cancer Research Group using smoothed hazard function. Cancer 86 : 1818─1826, 1999

4） Sylvester RJ, Oosterlinck W and van der Meijden AP : A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer : a meta-analysis of published results of randomized clinical trials. J Urol 171 : 2186─2190, 2004

5） Gudjónsson S, Adell L, Merdasa F, et al : Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study. Eur Urol 55 : 773─780, 2009

6） Sylvester RJ, Oosterlinck W, Holmang S, et al : Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa-pT1 Urothelial Carcinoma of the Bladder : Which Patients Benefit from the Instillation? Eur Urol pii : S0302─2838（15）00456-X, 2015［Epub ahead of print］

7） Akaza H, Isaka S, Koiso, et al : Comparative analysis of short-term and long-term prophylactic intravesical chemotherapy of superficial bladder cancer. Prospective, randomized, controlled studies of the Japanese Urological Cancer Research Group. Cancer Chemother Pharmacol 20 : S91─96, 1987

8） Akaza H, Koiso K, Kotake T, et al : Long-term results of intravesical chemoprophylaxis of superficial bladder cancer : experience of the Japanese Urological Cancer Research Group for Adriamycin. Cancer Chemother Pharmacol 30 : S15─20, 1992

9） Huncharek M, McGarry R and Kupelnick B : Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder : results of a meta-analysis. Anticancer Res 21 : 765─769, 2001

10） http://uroweb.org/wp-content/uploads/EAU-Guidelines-Non-muscle-invasive- Bladder-Cancer-2015-v1.pdf

11） Hendricksen K, Witjes WP, Idema JG, et al : Comparison of three schedules of intravesical epirubicin in patients with non-muscle-invasive bladder cancer. Eur Urol 53 : 984─991, 2008

12） Koupparis A, Casey RG, Robinson M, et al : Novel targeted agents on the horizon for castration-resistant prostate cancer. Future Oncol 6 : 1883─1895, 2010

13） Kikuchi E, Fujimoto H, Mizutani Y, et al : Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan : 1999-2001 report from the Japanese Urological Association. Int J Urol 16 : 279─286, 2009

14） Shelley MD, Mason MD and Kynaston H : Intravesical therapy for superficial bladder cancer : a systematic review of randomised trials and meta-analyses. Cancer Treat Rev 36 : 195─205, 2010

15） Hinotsu S, Akaza H, Naito S, et al : Maintenance therapy with bacillus Calmette-Guérin Connaught strain clearly prolongs recurrence-free survival following transurethral resection of bladder tumour for non-muscle-invasive bladder cancer. BJU Int 108 : 187─195, 2011

16） Malmström PU, Sylvester RJ, Crawford DE, et al : An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol 56 : 247─256, 2009

17） Persad R, Lamm D, Brausi M, et al : Current Approaches to the Management of Non-Muscle Invasive Bladder Cancer : Comparison of Current Guidelines and Recommendations. Eur Urol Supple 7 : 637─650, 2008

18） Sylvester RJ, van der meijden AP and Lamm DL : Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer : a meta-analysis of the published results of randomized clinical trials. J Urol 168 : 1964─1970, 2002